1. Anaplastic Lymphoma Kinase (ALK) Rearrangement-positive Lung Cancer with Transformation to Pleomorphic Carcinoma
   Yosuke Kamide et al, 2015, Intern. Med. CrossRef
2. miR-200c regulates crizotinib-resistant ALK-positive lung cancer cells by reversing epithelial-mesenchymal transition via targeting ZEB1
   Hai-Xiang Gao et al, 2016 CrossRef
3. Curcumin inhibits cell proliferation and induces apoptosis of human non-small cell lung cancer cells through the upregulation of miR-192-5p and suppression of PI3K/Akt signaling pathway
   HAI JIN et al, 2015 CrossRef
4. Understanding and targeting resistance mechanisms in NSCLC.
   Julia Rotow et al, 2017, Nat Rev Cancer CrossRef
5. p100 functions as a metastasis activator and is targeted by tumor suppressing microRNA-320a in lung cancer
   Aimin Xing et al, 2017, Thorac Cancer CrossRef
6. MicroRNA-1285-5p influences the proliferation and metastasis of non-small-cell lung carcinoma cells via downregulating CDH1 and Smad4
   Shixia Zhou et al, 2017, Tumour Biol. CrossRef
7. LncRNA ATB promotes proliferation and metastasis in A549 cells by down-regulation of microRNA-494
   Yiwei Cao et al, 2018, J. Cell. Biochem. CrossRef
8. Current Molecular-Targeted Therapies in NSCLC and Their Mechanism of Resistance
   Zachary Schrank et al, 2018, Cancers CrossRef
9. Drug Resistance in Non-Small Cell Lung Cancer: A Potential for NOTCH Targeting?
   Venus Sosa Iglesias et al, 2018, Front. Oncol. CrossRef
10. Hedgehog Signaling in Lung Cancer: From Oncogenesis to Cancer Treatment Resistance
    Etienne Giroux-Leprieur et al, 2018, IJMS CrossRef
11. Apatinib reverses alectinib resistance by targeting vascular endothelial growth factor receptor 2 and attenuating the oncogenic signaling pathway in echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase fusion gene-positive lung cancer cell lines
    Yanqiong Chen et al, 2018, Anti-Cancer Drugs CrossRef
12. null
    Francesco Facchinetti et al, 2017 CrossRef
13. The role of alectinib in the treatment of advanced ALK-rearranged non-small-cell lung cancer
    Srividya Srinivasamaharaj et al, 2016, Expert Review of Anticancer Therapy CrossRef
14. Metastasis manners and the underlying mechanisms of ALK and ROS1 rearrangement lung cancer and current possible therapeutic strategies
    Xing Chang et al, 2019, RSC Adv. CrossRef
15. GNAS-AS1/miR-4319/NECAB3 axis promotes migration and invasion of non-small cell lung cancer cells by altering macrophage polarization
    Zhixin Li et al, 2019, Funct Integr Genomics CrossRef
16. Modalités d’utilisation du ceritinib (Zykadia™), inhibiteur de ALK de 2e génération, dans le cancer bronchique non à petites cellules de stade avancé
    Etienne Giroux Leprieur et al, 2015, Bulletin du Cancer CrossRef
17. Crizotinib resistance: implications for therapeutic strategies.
    I Dagogo-Jack et al, 2016, Ann Oncol CrossRef
18. A tool for discovering drug sensitivity and gene expression associations in cancer cells
    Yong Qin et al, 2017, PLoS ONE CrossRef
19. Mechanistic Understanding of Curcumin’s Therapeutic Effects in Lung Cancer
    Wan Nur Baitty Wan Mohd Tajuddin et al, 2019, Nutrients CrossRef
20. Long non-coding RNA colon cancer-associated transcript-1 regulates tumor cell proliferation and invasion of non-small-cell lung cancer through suppressing miR-152
    Na Li et al, 2020, Geriatr. Gerontol. Int. CrossRef
21. Low expression of miR-192 in NSCLC and its tumor suppressor functions in metastasis via targeting ZEB2
    Zhang Yunxia et al, 2016 CrossRef
22. Oncogenic ALK regulates EMT in non-small cell lung carcinoma through repression of the epithelial splicing regulatory protein 1
    Claudia Voena et al, 2016, Oncotarget CrossRef
23. Targeting hypoxic response for cancer therapy
    Elisa Paolicchi et al, 2016, Oncotarget CrossRef
24. Early and late effects of pharmacological ALK inhibition on the neuroblastoma transcriptome
    Shana Claeys et al, 2017, Oncotarget CrossRef
25. Resistance to targeted therapies as a multifactorial, gradual adaptation to inhibitor specific selective pressures
    Robert Vander Velde et al, 2020, Nat Commun CrossRef
26. A bioinformatics investigation into the pharmacological mechanisms of javanica oil emulsion injection in non-small cell lung cancer based on network pharmacology methodologies
    Mengwei Ni et al, 2020, BMC Complement Med Ther CrossRef
27. Notch Transduction in Non-Small Cell Lung Cancer
    Amnah Sharif et al, 2020, IJMS CrossRef
28. Potential monoamine oxidase A inhibitor suppressing paclitaxel‐resistant non‐small cell lung cancer metastasis and growth
    Xiaoguang Yang et al, 2020, Thorac Cancer CrossRef
29. Combining Radiation Therapy with ALK Inhibitors in Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer (NSCLC): A Clinical and Preclinical Overview
    Delphine Antoni et al, 2021, Cancers CrossRef
30. Lung Cancer Management with Silibinin: A Historical and Translational Perspective
    Sara Verdura et al, 2021, Pharmaceuticals CrossRef
31. PRPS2 Enhances Resistance to Cisplatin via Facilitating Exosomes-mediated Macrophage M2 Polarization in Non-small Cell Lung Cancer
    Gaohua Liu et al, 2021, Immunological Investigations CrossRef
32. Knockdown of lncRNA HIF1A-AS2 increases drug sensitivity of SCLC cells in association with autophagy
    Ebru Güçlü et al, 2021, Med Oncol CrossRef
33. Clinical Impact of the Epithelial-Mesenchymal Transition in Lung Cancer as a Biomarker Assisting in Therapeutic Decisions.
    Julien Ancel et al, 2022, Cells Tissues Organs CrossRef
34. Resistance to Targeted Agents Used to Treat Paediatric ALK-Positive ALCL
    Lucy Hare et al, 2021, Cancers CrossRef
35. Therapeutic Targeting Hypoxia-Inducible Factor (HIF-1) in Cancer: Cutting Gordian Knot of Cancer Cell Metabolism
    Abhilasha Sharma et al, 2022, Front. Genet. CrossRef
36. The Molecular Role of IL-35 in Non-Small Cell Lung Cancer
    Yuqiu Hao et al, 2022, Front. Oncol. CrossRef
37. Updated Evidence on the Mechanisms of Resistance to ALK Inhibitors and Strategies to Overcome Such Resistance: Clinical and Preclinical Data
    Gouji Toyokawa et al, 2015, Oncol Res Treat CrossRef
38. Research Progress on the Drug Resistance of ALK Kinase Inhibitors
    Zhen Li et al, 2022, CMC CrossRef
39. Anti-migratory effect of curcumin on A-549 lung cancer cells via epigenetic reprogramming of RECK/ matrix metalloproteinase axis
    Shabnam Mostofi et al, 2022 CrossRef
40. Silibinin Overcomes EMT-Driven Lung Cancer Resistance to New-Generation ALK Inhibitors
    Sara Verdura et al, 2022, Cancers CrossRef
41. EML4‐ALK biology and drug resistance in non‐small cell lung cancer: a new phase of discoveries
    Mariam Elshatlawy et al, 2023, Molecular Oncology CrossRef
42. Anaplastic lymphoma kinase inhibitors—a review of anticancer properties, clinical efficacy, and resistance mechanisms
    Kajetan Kiełbowski et al, 2023, Front. Pharmacol. CrossRef
43. Prospective observational study to explore genes and proteins predicting efficacy and safety of brigatinib for ALK-gene rearranged non-small-cell lung cancer: study protocol for ABRAID study (WJOG11919L)
    Yuichi Ozawa et al, 2024, Ther Adv Med Oncol CrossRef